Infinity Pharmaceuticals (Infinity Pharmaceuticals) Operating Cash Flow per Share

: $-0.44 (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

Infinity Pharmaceuticals's operating cash flow per share for the three months ended in Jun. 2023 was $-0.09. Infinity Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.44.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 13.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Infinity Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

INFIQ' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -160.8 Med: 1.85 Max: 66.2
Current: 13.3

During the past 13 years, Infinity Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 66.20% per year. The lowest was -160.80% per year. And the median was 1.85% per year.

INFIQ's 3-Year OCF Growth Rate is ranked better than
60.03% of 1236 companies
in the Biotechnology industry
Industry Median: 3.5 vs INFIQ: 13.30

Infinity Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Infinity Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

-0.09

-0.73

-0.60

-0.48

Infinity Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Operating Cash Flow per Share																-0.12	-0.11	-0.10	-0.14	-0.09

Competitive Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infinity Pharmaceuticals Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Infinity Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Infinity Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-42.431	/	89.248
	=	-0.48

Infinity Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Jun. 2023 )	=	Cash Flow from Operations (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	-8.007	/	89.885
	=	-0.09

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44

Infinity Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138

Website

https://www.infi.com

Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.

Executives

Adelene Q Perkins	director, officer: President & CEO	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso	officer: Chief Scientific Officer	1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria	officer: Chief Medical Officer	1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok	officer: Chief Scientific Officer	784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch	officer: EVP, CFO & CBO
Michael Kauffman	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti	director